As noted in Wednesday morning's 'Biotech Snapshot', CytRx is on a roll of positive pipeline progress that has brought a bit of a rebound to the CYTR share price, which has modestly declined over the past few weeks.

Wednesday morning brought another dose of positive updates when it was announced that INNO-206, an experimental doxorubicin conjugate that targets cancerous tumors, is safely delivering doxorubicin at doses over four times higher than the standard in the ongoing Phase I soft tissue sarcomas trial.

CytRx retains global rights to INNO-206, and the FDA has recently granted an Orphan Drug Designation (ODD) to the product candidate, according to a release issued by the company earlier in the week. The ODD will grant CytRx seven years of market exclusivity for the soft tissue sarcomas indication, should INNO-206 make it that far.

Results to measure efficacy are still not ready for the Phase Ib trial, which is still ongoing, but a quick turnaround to a Phase IIb trial is planned for later this year.

To date, CytRx has seven clinical trials either under way or in the works, with bafetinib and tamibarotene already being tested in multiple Phase II trials.

The ENABLE trial is measuring bafetinib for effectiveness in high-risk B-cell chronic lymphocytic leukemia (B-CLL), while another Phase II - titled PROACT - tests the product candidate in advanced prostate cancer. A pharmacokinetic clinical trial is also being conducted for brain cancer.

Tamibarotene is being tested in a double-blind placebo-controlled Phase 2 trial in patients with non-small-cell lung cancer as well as in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL).
In continuing with the Phase Ib INNO-206 trial, CytRx will continue escalating dosage until finding the 'maximum threshold' of tolerance. It is expected that increasing the amount of doxorubicin in the bloodstream will also increase the efficacy of INNO-206's cancer-fighting abilities.

Being a 'Phase II' company, the more impatient investors tend to look for companies that will pay off in the shorter term, but when a 'Phase II' company becomes a 'Phase III' company, the share price could quickly adjust. I use KERX as the example for that one, since shares about quadrupled on news of successful Phase II completion and the initiation of Phase III trials.

With a share price inching higher, and multiple Phase II trials underway or in the planning phases, CYTR is one to keep on the radars right now.

Disclosure: No position.

Add a Comment